Clinical trials
Lysosomal Storage Diseases trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2011 | 5 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14 |
| Terminated | 3 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alexion Pharmaceuticals, Inc. | 4 |
| Shire | 4 |
| BioMarin Pharmaceutical | 3 |
| LYSOGENE | 2 |
| Spark Therapeutics, Inc. | 2 |
| ZevraDenmark | 2 |
| Azafaros B.V. | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
| University Hospital, Rouen | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lysosomal Storage Diseases | 20 |
| Cholesterol Ester Storage Disease | 4 |
| Wolman Disease | 4 |
| Mucopolysaccharidosis II | 3 |
| Mucopolysaccharidosis IV | 3 |
| Gangliosidosis, GM1 | 2 |
| Genetic Diseases, Inborn | 2 |
| Glycogen Storage Disease Type II | 2 |
| Mucopolysaccharidosis III | 2 |
| Nervous System Diseases | 2 |
Trials
Showing 76 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.